Document is current
Any future updates will be listed below
-
Authors
Lin, Ting-Hui
Lee, Chang-Chun David
Fernández-Quintero, Monica L.
Ferguson, James A.
Han, Julianna https://orcid.org/0000-0002-3402-2609
Zhu, Xueyong https://orcid.org/0000-0002-6021-3740
Yu, Wenli https://orcid.org/0000-0002-4025-2646
Guthmiller, Jenna J. https://orcid.org/0000-0001-7566-3536
Krammer, Florian https://orcid.org/0000-0003-4121-776X
Wilson, Patrick C. https://orcid.org/0000-0002-3537-1245
Ward, Andrew B. https://orcid.org/0000-0001-7153-3769
Wilson, Ian A. https://orcid.org/0000-0002-6469-2419
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93109C00051, 75N93109C00051, 75N93109C00051, 75N93109C00051, 75N93109C00051)
- License Information
-
More Information
Article History
Received: 5 October 2024
Accepted: 21 January 2025
First Online: 2 February 2025
Competing interests
: The authors declare the following competing interests. Florian Krammer is listed as a co-inventor on patent applications filed by The Icahn School of Medicine at Mount Sinai relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines, and influenza virus therapeutics. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. Florian Krammer is a co-founder and scientific advisory board member of Castlevax. Florian Krammer has consulted for Merck, CureVac, Seqirus, GSK, and Pfizer and is currently consulting for 3rd Rock Ventures, Sanofi, Gritstone and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development. Patrick Wilson and Jenna Guthmiller are listed as co-inventors on a patent application filed by the University of Chicago relating to anchor epitope targeting antibodies. The remaining Authors have no competing interests to declare.
